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Abstract
Hyperparathyroidism occurs in 20-30% of MEN2A syndrome patients. It is usually associated with mild disease and
is frequently asymptomatic, especially in younger age. There is genotype/phenotype association and PHP is usually
associated with codon 634 mutations; however association with more “rare” mutations has also been reported. The
pathology of the parathyroid glands includes hyperplasia, adenoma or a combination of the two. The optimal
surgical management of this entity has not been defined yet.
Background
The parathyroids are involved in the multiple endocrine
neoplasia (MEN2) syndromes more rarely than the other
two endocrine organs affected (c cells and adrenal
medulla). The prevalence of PHP varies between 20-30%
in MEN2A. In the majority of cases hyperplasia precedes
the development of adenoma formation. However both
may co-exist or even a single adenoma may be found at
operation. One of the clinical features characteristic of pri-
mary hyperparathyroidism in the context of the MEN2
syndromes is the younger age at presentation. European
studies have shown that the majority of cases are diag-
nosed before age 39; furthermore, most of the patients are
asymptomatic at PHP diagnosis [1]. A few studies have
been published concerning associations between specific
ret codons and the occurrence of PHP in familial MTC. It
appears that there is a genotype/phenotype correlation
concerning this manifestation of MEN2, as the majority of
PHP cases cluster with exon 11 mutations and specifically
with the 634 codon mutation [2-4]. Hyperparathyroidism
has occasionally been reported in association with other
ret gene mutated codons such as codons 611, 618, 620,
630 etc.
One of the important issues concerning the manage-
ment of PHP in MEN syndromes in general is the ability
to recognize single gland versus multiple gland disease
and subsequently decide on the surgical procedure to be
followed so that recurrences can be avoided. The following
procedures are applied in practice depending on the num-
ber of glands involved: total parathyroidectomy with auto-
transplantation, subtotal parathyroidectomy, or single
gland removal. One other problem is the occurrence of
permanent hypoparathyroidism in some cases; this com-
plication is usually associated with total parathyroidect-
omy. However, hypoparathyroidism has also been
reported after subtotal parathyroidectomy, or even after
excision of 2 glands [5]. Re operation can be performed
when recurrent disease is diagnosed, but this is not always
followed by cure. Successful use of calcimimetics has been
reported in cases of disease persistence [6].
The use of total parathyroidectomy with autotransplan-
tation at the time of primary surgery is popular in some
centres [5,7], but is not routine practice in Europe [3,8,9].
Comments to the ATA guidelines
There are no major differences between the European
approach and the ATA approach on this issue. It is inter-
esting that all the recommendations are grade C. Recom-
mendation 26: screening for PHP is necessary in
asymptomatic ret mutation carriers. The ATA proposes
to start the screening by age 8 in the cases carrying muta-
tions in those codons which are frequently associated
with the occurrence of PHP.
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Comment: universally starting at the age of 8 years
appears a little early as the median age at presentation is
38 years [10]. There are only few cases of PHP presenting
before the third decade; furthermore PHP appears to be
generally mild in young subjects with MEN2 syndrome
[1]. We thus believe age 20 seems more appropriate if
there are no specific family data for earlier appearance.
Yearly checking is optimal as the calcium estimation is
an inexpensive and simple blood test.
Recommendations 47-50. These recommendations con-
cern the optimal surgical treatment for PHP in MEN2.
Comment. The optimal surgical treatment is not yet
defined especially in a previously thyroidectomised
patient; therefore, the consequences of the PHP in these
patients should be assessed per individual patient and the
decision for surgery should be reached accordingly. This
view is based on the fact that there is a substantial rate of
both permanent hypoparathyroidism as well as recur-
rent/persistent hyperparathyroidism in most published
series [3,5]. On the other hand in the majority of young
patients the hyperparathyroidism is “asymptomatic” [10].
In recent years less invasive methods are used [9].
List of abbreviations used
MEN2: multiple endocrine neoplasia type 2; MTC: medullary thyroid
carcinoma; PHP: primary hyperparathyroidism.
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